Trelagliptin stimulates osteoblastic differentiation by increasing runt-related transcription factor 2 (RUNX2): a therapeutic implication in osteoporosis

References

• Appelman-Dijkstra NM, Papapoulos SE. Modulating bone resorption and bone formation in opposite directions in the treatment of postmenopausal osteoporosis. Drugs. 2015;75(10):1049–1058.
   PubMed Web of Science ®Google Scholar
• Takeshita S. [Coupling of bone resorption and formation.]. Clin Calcium. 2017;27(12):1705–1711.
   PubMedGoogle Scholar
• Liu Z, Liang W, Kang D, et al. Increased osteoblastic CXCL9 contributes to the uncoupled bone formation and resorption in postmenopausal osteoporosis. Clin Interv Aging. 2020;15:1201–1212.
   PubMed Web of Science ®Google Scholar
• Hongo T, Kotake K, Muramatsu H, et al. Loss of bone mineral density following sepsis using Hounsfield units by computed tomography. Acute Med Surg. 2019;6(2):173–179.
   PubMed Web of Science ®Google Scholar
• Mukherjee K, Chattopadhyay N. Pharmacological inhibition of cathepsin K: a promising novel approach for postmenopausal osteoporosis therapy. Biochem Pharmacol. 2016;117:10–19.
   PubMed Web of Science ®Google Scholar
• Armas LA, Recker RR. Pathophysiology of osteoporosis: new mechanistic insights. Endocrinol Metab Clin North Am. 2012;41(3):475–486.
   PubMed Web of Science ®Google Scholar
• Baccaro LF, Conde DM, Costa-Paiva L, et al. The epidemiology and management of postmenopausal osteoporosis: a viewpoint from Brazil. Clin Interv Aging. 2015;10:583–591.
   PubMed Web of Science ®Google Scholar
• Wang C, Meng H, Wang X, et al. Differentiation of bone marrow mesenchymal stem cells in osteoblasts and adipocytes and its role in treatment of osteoporosis. Med Sci Monit. 2016;22:226–233.
   PubMed Web of Science ®Google Scholar
• Komori T. Runx2, an inducer of osteoblast and chondrocyte differentiation. Histochem Cell Biol. 2018;149(4):313–323.
   PubMed Web of Science ®Google Scholar
• Komori T. Regulation of proliferation, differentiation and functions of osteoblasts by Runx2. Int J Mol Sci. 2019;20(7):1694.
   Web of Science ®Google Scholar
• Nguyen V, Meyers CA, Yan N, et al. BMP-2-induced bone formation and neural inflammation. J Orthop. 2017;14(2):252–256.
   PubMed Web of Science ®Google Scholar
• Gaoli X, Yi L, Lili W, et al. [Effect of naringin combined with bone morphogenetic protein-2 on the proliferation and differentiation of MC3T3-E1 cells]. Hua Xi Kou Qiang Yi Xue Za Zhi. 2017;35(3):275–280.
   PubMedGoogle Scholar
• Dai J, Li Y, Zhou H, et al. Genistein promotion of osteogenic differentiation through BMP2/SMAD5/RUNX2 signaling. Int J Biol Sci. 2013;9(10):1089–1098.
   PubMed Web of Science ®Google Scholar
• Lee YS, Kim YS, Lee SY, et al. AMP kinase acts as a negative regulator of RANKL in the differentiation of osteoclasts. Bone. 2010;47(5):926–937.
   PubMed Web of Science ®Google Scholar
• Shah M, Kola B, Bataveljic A, et al. AMP-activated protein kinase (AMPK) activation regulates in vitro bone formation and bone mass. Bone. 2010;47(2):309–319.
   PubMed Web of Science ®Google Scholar
• Kang H, Viollet B, Wu D. Genetic deletion of catalytic subunits of AMP-activated protein kinase increases osteoclasts and reduces bone mass in young adult mice. J Biol Chem. 2013;288(17):12187–12196.
   PubMed Web of Science ®Google Scholar
• Wei J, Shimazu J, Makinistoglu MP, et al. Glucose uptake and Runx2 synergize to orchestrate osteoblast differentiation and bone formation. Cell. 2015;161(7):1576–1591.
   PubMed Web of Science ®Google Scholar
• McKeage K. Trelagliptin: first global approval. Drugs. 2015;75(10):1161–1164.
   PubMed Web of Science ®Google Scholar
• Kaku K. Safety evaluation of trelagliptin in the treatment of Japanese type 2 diabetes mellitus patients. Expert Opin Drug Saf. 2017;16(11):1313–1322.
   PubMed Web of Science ®Google Scholar
• Kaku K. First novel once-weekly DPP-4 inhibitor, trelagliptin, for the treatment of type 2 diabetes mellitus. Expert Opin Pharmacother. 2015;16(16):2539–2547.
   PubMed Web of Science ®Google Scholar
• Yang Y, Zhao C, Liang J, et al. Effect of dipeptidyl peptidase-4 inhibitors on bone metabolism and the possible underlying mechanisms. Front Pharmacol. 2017;8:487.
   PubMed Web of Science ®Google Scholar
• Hayakawa N, Suzuki A. [Diabetes mellitus and osteoporosis. Effect of antidiabetic medicine on osteoporotic fracture]. Clin Calcium. 2012;22(9):1383–1390.
   PubMedGoogle Scholar
• Chen Q, Liu T, Zhou H, et al. Risk of fractures associated with dipeptidyl peptidase-4 inhibitor treatment: a systematic review and meta-analysis of randomized controlled trials. Diabetes Ther. 2019;10(5):1879–1892.
   PubMed Web of Science ®Google Scholar
• Qi X, Zhang J, Yuan H, et al. Exosomes secreted by human-induced pluripotent stem cell-derived mesenchymal stem cells repair critical-sized bone defects through enhanced angiogenesis and osteogenesis in osteoporotic rats. Int J Biol Sci. 2016;12(7):836–849.
   PubMed Web of Science ®Google Scholar
• Sun Y, Liu Y, He W, et al. Cajaninstilbene acid inhibits osteoporosis through suppressing osteoclast formation and RANKL-induced signaling pathways. J Cell Physiol. 2019;234(7):11792–11804.
   PubMed Web of Science ®Google Scholar
• Liu Z, Xu L, Xing M, et al. Trelagliptin succinate: DPP-4 inhibitor to improve insulin resistance in adipocytes. Biomed Pharmacother. 2020;125:109952.
   PubMed Web of Science ®Google Scholar
• Liu CF, Samsa WE, Zhou G, et al. Transcriptional control of chondrocyte specification and differentiation. Semin Cell Dev Biol. 2017;62:34–49.
   PubMed Web of Science ®Google Scholar
• Stock M, Otto F. Control of RUNX2 isoform expression: the role of promoters and enhancers. J Cell Biochem. 2005;95(3):506–517.
   PubMed Web of Science ®Google Scholar
• Komori T. Roles of Runx2 in skeletal development. Adv Exp Med Biol. 2017;962:83–93.
   PubMed Web of Science ®Google Scholar
• Otto F, Thornell AP, Crompton T, et al. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell. 1997;89(5):765–771.
   PubMed Web of Science ®Google Scholar
• Komori T, Yagi H, Nomura S, et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell. 1997;89(5):755–764.
   PubMed Web of Science ®Google Scholar
• Takarada T, Hinoi E, Nakazato R, et al. An analysis of skeletal development in osteoblast-specific and chondrocyte-specific runt-related transcription factor-2 (Runx2) knockout mice. J Bone Miner Res. 2013;28(10):2064–2069.
   PubMed Web of Science ®Google Scholar
• Byers BA, Guldberg RE, Garcia AJ. Synergy between genetic and tissue engineering: runx2 overexpression and in vitro construct development enhance in vivo mineralization. Tissue Eng. 2004;10(11–12):1757–1766.
   PubMedGoogle Scholar
• Zhou S, Huang G, Chen G. Synthesis and biological activities of drugs for the treatment of osteoporosis. Eur J Med Chem. 2020;197:112313.
   PubMed Web of Science ®Google Scholar
• Ching HS, Luddin N, Rahman IA, et al. Expression of odontogenic and osteogenic markers in DPSCs and SHED: a review. Curr Stem Cell Res Ther. 2017;12(1):71–79.
   PubMed Web of Science ®Google Scholar
• Cortizo AM, Sedlinsky C, McCarthy AD, et al. Osteogenic actions of the anti-diabetic drug metformin on osteoblasts in culture. Eur J Pharmacol. 2006;536(1–2):38–46.
   PubMed Web of Science ®Google Scholar
• Kanazawa I, Yamaguchi T, Yano S, et al. Metformin enhances the differentiation and mineralization of osteoblastic MC3T3-E1 cells via AMP kinase activation as well as eNOS and BMP-2 expression. Biochem Biophys Res Commun. 2008;375(3):414–419.
   PubMed Web of Science ®Google Scholar
• Kanazawa I, Yamaguchi T, Yano S, et al. AMP kinase activator stimulate proliferation, differentiation, and mineralization of osteoblastic MC3T3-E1 cells. BMC Cell Biol. 2007;8(1):51.
   PubMedGoogle Scholar
• Lee W, Ko KR, Kim HK, et al. Dehydrodiconiferyl alcohol promotes BMP-2-induced osteoblastogenesis through its agonistic effects on estrogen receptor. Biochem Biophys Res Commun. 2018;495(3):2242–2248.
   PubMed Web of Science ®Google Scholar
• Yang Y, Fan C, Deng C, et al. Melatonin reverses flow shear stress-induced injury in bone marrow mesenchymal stem cells via activation of AMP-activated protein kinase signaling. J Pineal Res. 2016;60(2):228–241.
   PubMed Web of Science ®Google Scholar